Syncom Formulations (India) Limited

BSE: 524470
Syncom Formulations (India) Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials and compliance.
CIN L24239MH1988PLC047759 Incorporated 21 June 1988 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - BSE: 524470 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹489.17 Cr
▲ 5.2% YoY
EBITDA · FY 2026
₹108.77 Cr
▲ 51.99% YoY
Net profit · FY 2026
₹76.44 Cr
▲ 54.62% YoY
Authorised capital
₹95 Cr
Registered with MCA
Paid-up capital
₹94 Cr
Issued & subscribed
Open charges
₹9.5 Cr
Satisfied ₹156.68 Cr
Company age
38 yrs
Est. 1988
Employees · EPFO
681
Latest available

About Syncom Formulations (India) Limited

Data last updated: 18 December 2025

Syncom Formulations (India) Limited is a public limited company based in Mumbai, Maharashtra, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 21 June 1988, the company has been in operation for over 38 years.

Registered with ROC Mumbai under CIN L24239MH1988PLC047759. Listed on BSE: 524470.

Capital: an authorised share capital of ₹95 Cr and a paid-up capital of ₹94 Cr. Formerly known as Syncom Formulations (India) Pvt Limited. It is led by directors including Ritesh Kumar Lunkad and Ankit Jain.

Last AGM: 30 September 2024. Financial statements filed for year ended 31 March 2025. Office: 7 Niraj Industrial Estate Off Mahakali Caves Road Andheri (East), Mumbai, Maharashtra, India – 400093.

As per the financials filed for FY 2025, the company reported a revenue of ₹482.45 Cr, a growth of 74% compared to the previous year.

The company has a workforce of approximately 681 employees as per the latest available data. Its group structure includes 3 subsidiaries.

The company is associated with 1 brand - Syncom Formulations. As per MCA filings, the company has open charges of ₹9.5 Cr and satisfied charges of ₹156.68 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website sfil.in.

Company Details of Syncom Formulations (India) Limited
CIN L24239MH1988PLC047759
Registration Number 047759
Incorporation Date 21 June 1988
ROC Mumbai
Listing Status Listed (BSE: 524470)
Company Status Active
Date of Last AGM 30 September 2024
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Kedarmal Shankarlal Bankda Whole-Time Director Ankit Kedarmal Bankda Whole-Time Director Rinki Ankit Bankda Whole-Time Director
Contact Details
  • Email
    *****@*****.com
  • Telephone
    +91-****-******
  • Website
    sfil.in
  • Social Media
    **************
  • Registered Address
    7 Niraj Industrial Estate Off Mahakali Caves Road Andheri (East), Mumbai, Maharashtra, India – 400093
  • Industry
    Pharma, Drug Formulation & Development
Company report
Syncom Formulations (India) Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Syncom Formulations (India) Limited report

Financials, compliance, directors, charges, ownership and filings for Syncom Formulations (India) Limited in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Syncom Formulations (India) Limited

Syncom Formulations (India) Limited has one previous CIN (Corporate Identification Number): U24239MH1988PLC047759. The current CIN is L24239MH1988PLC047759, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L24239MH1988PLC047759 Current
U24239MH1988PLC047759 Previous

Associated Brands with Syncom Formulations (India) Limited

Syncom Formulations (India) Limited operates one associated brand: Syncom Formulations. These brands represent Syncom Formulations (India) Limited's diversified market presence and brand portfolio.

Brand Description Website
Syncom Formulations
Pharmaceutical formulations are manufactured and exported in various dosage forms. syncomformulations.com

Business Activity of Syncom Formulations (India) Limited

Syncom Formulations (India) Limited is engaged in principal business activities including manufacturing and trade, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products, wholesale trading. The company has 2 registered principal business activity segments, demonstrating its operational diversity and market reach.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products *********
G Trade G1 Wholesale Trading *********

Auditor Details of Syncom Formulations (India) Limited

Syncom Formulations (India) Limited is audited by Sanjay Mehta And Associates, Chartered Accountants (ICAI peer reviewed, certificate valid till 2027-03-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
Sanjay Mehta And Associates, Chartered Accountants (ICAI peer reviewed, certificate valid till 2027-03-31) FY 2026 Declaration of unmodified opinion

Board of Directors of Syncom Formulations (India) Limited

Syncom Formulations (India) Limited is currently managed by 10 directors, with 18 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Ritesh Kumar Lunkad
Also directs: Syncom Formulations (India) Limited
Director 14 Aug 2023 2 Years 10 Months Current
Ankit Jain
Also directs: Syncom Formulations (India) Limited
Director 14 Aug 2023 2 Years 10 Months Current
Kedarmal Shankarlal Bankda
Also directs: Syncom Formulations (India) Limited, Sante Biotech Private Limited, Synmex Pharma Private Limited and 1 more
Whole-Time Director 13 Apr 1992 34 Years 2 Months Current
Vijay Shankarlal Bankda
Also directs: Syncom Formulations (India) Limited, Sante Biotech Private Limited, Synmex Pharma Private Limited and 1 more
Officer In Default 08 Aug 2025 0 Years 11 Months Current
Rahul Vijay Bankda
Also directs: Syncom Formulations (India) Limited, Paradise Vyapaar Private Limited
Cfo 09 Aug 2025 0 Years 11 Months Current
Ruchi Jindal
Also directs: Syncom Formulations (India) Limited
Director 28 Jun 2022 4 Years 0 Months Current
Showing 6 of 10 current directors. View all directors

Financials of Syncom Formulations (India) Limited FY 2026 filings available

Syncom Formulations (India) Limited reported revenue of ₹489.17 Cr (up 5.2% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.

Revenue · FY 2026
₹489.17 Cr ▲ 5.2%
Profit · FY 2026
₹76.44 Cr ▲ 54.62%
EBITDA · FY 2026
₹108.77 Cr ▲ 51.99%
Revenue₹ Cr · Consolidated0200400600FY 2023: ₹224 Cr224FY 2023FY 2024: ₹263 Cr · +17.5% YoY263+17.5%FY 2024FY 2025: ₹465 Cr · +76.6% YoY465+76.6%FY 2025FY 2026: ₹489 Cr · +5.2% YoY489+5.2%FY 2026
Net Profit₹ Cr · Consolidated050100FY 2023: ₹20 Cr20.1FY 2023FY 2024: ₹25 Cr · +26.1% YoY25.3+26.1%FY 2024FY 2025: ₹49 Cr · +95.3% YoY49.4+95.3%FY 2025FY 2026: ₹76 Cr · +54.6% YoY76.4+54.6%FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year050100150Q1'25: ₹87 Cr · +45.8% YoY87.3+45.8%Q1'25Q2'25: ₹102 Cr · +60.3% YoY102+60.3%Q2'25Q3'25: ₹128 Cr · +95.8% YoY128+95.8%Q3'25Q4'25: ₹149 Cr · +99.6% YoY149+99.6%Q4'25Q1'26: ₹117 Cr · +34% YoY117+34%Q1'26Q2'26: ₹122 Cr · +19% YoY122+19%Q2'26Q3'26: ₹115 Cr · -9.7% YoY115-9.7%Q3'26Q4'26: ₹135 Cr · -9% YoY135-9%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Revenue from Operations ₹489.17 Cr ₹465.01 Cr ₹263.39 Cr ₹224.25 Cr
Other Income ₹31.34 Cr ₹17.43 Cr ₹13.53 Cr ₹14.6 Cr
Total Income ₹520.51 Cr ₹482.45 Cr ₹276.91 Cr ₹238.85 Cr
Cost of Materials Consumed ₹220.94 Cr ₹278.03 Cr ₹131.53 Cr ₹99.46 Cr
Purchases of Stock-in-Trade ₹67.23 Cr ₹39.97 Cr ₹27.11 Cr ₹42.61 Cr
Changes in Inventories -₹3.89 Cr -₹10.66 Cr -₹1.75 Cr -₹37.61 Lakh
Employee Benefit Expense ₹67.09 Cr ₹52.17 Cr ₹35.06 Cr ₹25.87 Cr
Finance Costs ₹1.16 Cr ₹86.49 Lakh ₹4.47 Cr ₹3.13 Cr
Depreciation & Amortisation ₹6.53 Cr ₹5.19 Cr ₹4.72 Cr ₹4.54 Cr
Other Expenses ₹60.38 Cr ₹51.37 Cr ₹41.8 Cr ₹37.06 Cr
Total Expenses ₹419.43 Cr ₹416.94 Cr ₹242.94 Cr ₹212.29 Cr
Profit Before Exceptional Items & Tax ₹101.08 Cr ₹65.51 Cr ₹33.98 Cr ₹26.56 Cr
Exceptional Items ₹3.69 Lakh ₹58,000 -₹2.39 Lakh ₹1.33 Lakh
Profit Before Tax ₹101.12 Cr ₹65.51 Cr ₹33.95 Cr ₹26.57 Cr
Total Tax Expense ₹24.68 Cr ₹16.08 Cr ₹8.64 Cr ₹6.5 Cr
Net Profit ₹76.44 Cr ₹49.43 Cr ₹25.31 Cr ₹20.07 Cr
  attributable to Owners ₹0 ₹0 - ₹0
  attributable to NCI ₹0 ₹0 - ₹0
Other Comprehensive Income -₹3.61 Cr ₹4.58 Cr ₹6.81 Cr ₹1.96 Cr
Total Comprehensive Income ₹72.83 Cr ₹54.01 Cr ₹32.13 Cr ₹22.03 Cr
EBITDA (computed) ₹108.77 Cr ₹71.57 Cr ₹43.17 Cr ₹34.23 Cr
Basic EPS ₹0.81 ₹0.57 ₹0.34 ₹0.24
Diluted EPS ₹0.81 ₹0.57 ₹0.34 ₹0.24
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹533.85 Cr ₹413.28 Cr ₹404.66 Cr ₹377.83 Cr
Non-current Assets ₹203.48 Cr ₹143.31 Cr ₹129.88 Cr ₹196.14 Cr
Current Assets ₹330.37 Cr ₹269.97 Cr ₹274.78 Cr ₹181.69 Cr
Property, Plant & Equipment ₹89.77 Cr ₹77.53 Cr ₹72.31 Cr ₹43.22 Cr
Inventories ₹62.88 Cr ₹41.33 Cr ₹21.08 Cr ₹21.2 Cr
Trade Receivables ₹110.5 Cr ₹107.55 Cr ₹103.3 Cr ₹75.51 Cr
Cash & Equivalents ₹5.15 Cr ₹71.2 Lakh ₹63.38 Cr ₹87.97 Lakh
Equity (Net Worth) ₹414.99 Cr ₹342.16 Cr ₹288.14 Cr ₹256.01 Cr
Equity Share Capital ₹94 Cr ₹94 Cr ₹94 Cr ₹94 Cr
Borrowings (Non-current) ₹0 ₹0 ₹0 ₹0
Borrowings (Current) ₹1.47 Cr ₹4.58 Cr ₹72.49 Cr ₹83.18 Cr
Total Debt (computed) ₹1.47 Cr ₹4.58 Cr ₹72.49 Cr ₹83.18 Cr
Current Liabilities ₹103.73 Cr ₹59.31 Cr ₹106.52 Cr ₹113.16 Cr
Total Liabilities ₹118.86 Cr ₹71.12 Cr ₹116.52 Cr ₹121.82 Cr
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Operating Cash Flow ₹58.08 Cr ₹23.44 Cr -₹5.96 Cr ₹10.53 Cr
Investing Cash Flow -₹50.62 Cr -₹18.2 Cr ₹83.02 Cr -₹44.95 Cr
Financing Cash Flow -₹3.02 Cr -₹67.9 Cr -₹14.56 Cr ₹35 Cr
Capital Expenditure ₹11.67 Cr ₹9.96 Cr ₹8.14 Cr ₹20.63 Cr
Free Cash Flow (computed) ₹46.41 Cr ₹13.48 Cr -₹14.09 Cr -₹10.11 Cr
Dividends Paid ₹0 ₹0 ₹0 ₹2.82 Cr
Net Change in Cash ₹4.44 Cr -₹62.67 Cr ₹62.5 Cr ₹57.8 Lakh
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹135.41 Cr ₹115.14 Cr ₹121.72 Cr ₹116.9 Cr ₹148.88 Cr ₹127.53 Cr ₹102.31 Cr ₹87.26 Cr ₹74.57 Cr ₹65.14 Cr ₹63.84 Cr ₹59.84 Cr
Other Income ₹14.55 Cr ₹5.5 Cr ₹5.25 Cr ₹6.03 Cr ₹6.94 Cr ₹4.04 Cr ₹4.15 Cr ₹1.34 Cr ₹3.1 Cr ₹4.56 Cr ₹4 Cr ₹1.87 Cr
Total Income ₹149.97 Cr ₹120.64 Cr ₹126.97 Cr ₹122.94 Cr ₹155.82 Cr ₹131.57 Cr ₹106.46 Cr ₹88.59 Cr ₹77.67 Cr ₹69.69 Cr ₹67.84 Cr ₹61.71 Cr
Cost of Materials Consumed ₹67.45 Cr ₹47.45 Cr ₹46.43 Cr ₹59.61 Cr ₹80.16 Cr ₹76.26 Cr ₹68.58 Cr ₹53.03 Cr ₹37.88 Cr ₹37.75 Cr ₹33.25 Cr ₹22.65 Cr
Purchases of Stock-in-Trade ₹20.55 Cr ₹15.71 Cr ₹15.29 Cr ₹15.68 Cr ₹15.79 Cr ₹7.23 Cr ₹12.66 Cr ₹4.29 Cr ₹5.02 Cr ₹4.5 Cr ₹8.37 Cr ₹9.21 Cr
Changes in Inventories -₹4.68 Cr -₹2.12 Cr ₹9.04 Cr -₹6.12 Cr ₹4.41 Cr ₹3.17 Cr -₹15.44 Cr -₹2.8 Cr -₹20.04 Lakh -₹2.72 Cr -₹2.52 Cr ₹3.68 Cr
Employee Benefit Expense ₹16.95 Cr ₹17.45 Cr ₹16.73 Cr ₹15.95 Cr ₹14.97 Cr ₹13.95 Cr ₹12.4 Cr ₹9.65 Cr ₹8.69 Cr ₹9.74 Cr ₹9 Cr ₹7.63 Cr
Finance Costs ₹37.59 Lakh ₹26.34 Lakh ₹26.49 Lakh ₹25.08 Lakh ₹11.68 Lakh ₹19.82 Lakh ₹15.96 Lakh ₹39.03 Lakh ₹1.2 Cr ₹1.08 Cr ₹1.08 Cr ₹1.12 Cr
Depreciation & Amortisation ₹2.48 Cr ₹1.36 Cr ₹1.35 Cr ₹1.34 Cr ₹1.29 Cr ₹1.31 Cr ₹1.3 Cr ₹1.3 Cr ₹1.3 Cr ₹1.45 Cr ₹87.88 Lakh ₹1.1 Cr
Other Expenses ₹13.14 Cr ₹15.44 Cr ₹15.83 Cr ₹15.97 Cr ₹15.78 Cr ₹12.2 Cr ₹11.95 Cr ₹12.64 Cr ₹13.76 Cr ₹8.52 Cr ₹9.33 Cr ₹10.2 Cr
Total Expenses ₹116.26 Cr ₹95.55 Cr ₹104.93 Cr ₹102.69 Cr ₹132.53 Cr ₹114.31 Cr ₹91.61 Cr ₹78.49 Cr ₹67.64 Cr ₹60.31 Cr ₹59.39 Cr ₹55.6 Cr
Profit Before Exceptional Items & Tax ₹33.71 Cr ₹25.09 Cr ₹22.04 Cr ₹20.25 Cr ₹23.29 Cr ₹17.26 Cr ₹14.85 Cr ₹10.1 Cr ₹10.03 Cr ₹9.39 Cr ₹8.45 Cr ₹6.11 Cr
Exceptional Items -₹44,000 ₹0 ₹0 ₹4.13 Lakh ₹82,000 ₹0 ₹0 ₹0 ₹0 -₹2.39 Lakh ₹0 ₹0
Profit Before Tax ₹33.7 Cr ₹25.09 Cr ₹22.04 Cr ₹20.29 Cr ₹23.3 Cr ₹17.26 Cr ₹14.85 Cr ₹10.1 Cr ₹10.03 Cr ₹9.36 Cr ₹8.45 Cr ₹6.11 Cr
Total Tax Expense ₹8.53 Cr ₹6.18 Cr ₹5.44 Cr ₹4.54 Cr ₹5.61 Cr ₹4.26 Cr ₹3.74 Cr ₹2.47 Cr ₹2.63 Cr ₹2.36 Cr ₹1.94 Cr ₹1.72 Cr
Net Profit ₹25.17 Cr ₹18.91 Cr ₹16.6 Cr ₹15.75 Cr ₹17.69 Cr ₹13 Cr ₹11.11 Cr ₹7.63 Cr ₹7.4 Cr ₹7 Cr ₹6.51 Cr ₹4.4 Cr
  attributable to Owners ₹0 ₹0 ₹0 - ₹0 ₹0 - ₹0 - ₹0 ₹0 -
  attributable to NCI ₹0 ₹0 ₹0 - ₹0 ₹0 - ₹0 - ₹0 ₹0 -
Other Comprehensive Income -₹9.95 Cr ₹2.36 Cr -₹5.58 Lakh ₹4.04 Cr -₹2.28 Cr ₹18.4 Lakh ₹3.92 Cr ₹2.76 Cr ₹1.65 Cr ₹1.86 Cr ₹1.24 Cr ₹2.07 Cr
Total Comprehensive Income ₹15.22 Cr ₹21.27 Cr ₹16.55 Cr ₹19.79 Cr ₹15.41 Cr ₹13.19 Cr ₹15.03 Cr ₹10.39 Cr ₹9.05 Cr ₹8.86 Cr ₹7.76 Cr ₹6.46 Cr
EBITDA (computed) ₹36.57 Cr ₹26.71 Cr ₹23.65 Cr ₹21.84 Cr ₹24.7 Cr ₹18.77 Cr ₹16.31 Cr ₹11.79 Cr ₹12.52 Cr ₹11.91 Cr ₹10.4 Cr ₹8.33 Cr
Basic EPS ₹0.27 ₹0.23 ₹0.18 ₹0.21 ₹0.16 ₹0.14 ₹0.16 ₹0.11 ₹0.10 ₹0.09 ₹0.08 ₹0.07
Diluted EPS ₹0.27 ₹0.23 ₹0.18 ₹0.21 ₹0.16 ₹0.14 ₹0.16 ₹0.11 ₹0.10 ₹0.09 ₹0.08 ₹0.07
Latest 12 quarters shown.
Segment · Q4 FY26 (latest quarter) Revenue Result (PBIT) Assets Liabilities
Pharmaceuticals Drugs & Formulations ₹149 Cr ₹33.72 Cr ₹439.76 Cr ₹117.14 Cr
Trading of Commodities ₹4.03 Lakh -₹4.35 Lakh ₹66.51 Lakh ₹4.12 Lakh
Renting of Property ₹92.04 Lakh ₹40.54 Lakh ₹93.42 Cr ₹1.68 Cr
Segment · FY 2026 (annual) Revenue Result (PBIT) Assets Liabilities
Pharmaceuticals Drugs & Formulations ₹515.73 Cr ₹99.32 Cr - -
Trading of Commodities ₹1.1 Cr -₹2.63 Lakh - -
Renting of Property ₹3.68 Cr ₹2.98 Cr - -
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Revenue from Operations ₹486.57 Cr ₹462.85 Cr ₹258.36 Cr ₹224.64 Cr
Other Income ₹30.97 Cr ₹17.19 Cr ₹13.1 Cr ₹14.61 Cr
Total Income ₹517.54 Cr ₹480.04 Cr ₹271.46 Cr ₹239.25 Cr
Cost of Materials Consumed ₹220.94 Cr ₹278.03 Cr ₹131.53 Cr ₹99.46 Cr
Purchases of Stock-in-Trade ₹66.7 Cr ₹39.48 Cr ₹26.21 Cr ₹42.61 Cr
Changes in Inventories -₹3.9 Cr -₹10.62 Cr -₹2.18 Cr ₹5.03 Lakh
Employee Benefit Expense ₹67.09 Cr ₹52.17 Cr ₹35.06 Cr ₹25.87 Cr
Finance Costs ₹1.1 Cr ₹85.02 Lakh ₹4.45 Cr ₹3.13 Cr
Depreciation & Amortisation ₹6.53 Cr ₹5.19 Cr ₹4.72 Cr ₹4.54 Cr
Other Expenses ₹58.59 Cr ₹50.29 Cr ₹39.89 Cr ₹37.04 Cr
Total Expenses ₹417.05 Cr ₹415.39 Cr ₹239.68 Cr ₹212.7 Cr
Profit Before Exceptional Items & Tax ₹100.49 Cr ₹64.65 Cr ₹31.78 Cr ₹26.55 Cr
Exceptional Items ₹3.69 Lakh ₹58,000 -₹2.39 Lakh ₹1.33 Lakh
Profit Before Tax ₹100.53 Cr ₹64.66 Cr ₹31.76 Cr ₹26.57 Cr
Total Tax Expense ₹24.52 Cr ₹15.79 Cr ₹8.14 Cr ₹6.5 Cr
Net Profit ₹76.01 Cr ₹48.87 Cr ₹23.62 Cr ₹20.07 Cr
Other Comprehensive Income -₹3.61 Cr ₹4.58 Cr ₹6.81 Cr ₹1.96 Cr
Total Comprehensive Income ₹72.4 Cr ₹53.45 Cr ₹30.44 Cr ₹22.03 Cr
EBITDA (computed) ₹108.13 Cr ₹70.7 Cr ₹40.95 Cr ₹34.22 Cr
Basic EPS ₹0.81 ₹0.57 ₹0.32 ₹0.24
Diluted EPS ₹0.81 ₹0.57 ₹0.32 ₹0.24
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹529.26 Cr ₹409.69 Cr ₹391.5 Cr ₹376.94 Cr
Non-current Assets ₹203.23 Cr ₹142.22 Cr ₹128.86 Cr ₹196.17 Cr
Current Assets ₹326.03 Cr ₹267.46 Cr ₹262.64 Cr ₹180.77 Cr
Property, Plant & Equipment ₹89.77 Cr ₹77.53 Cr ₹72.31 Cr ₹43.22 Cr
Inventories ₹62.85 Cr ₹41.29 Cr ₹21.08 Cr ₹20.77 Cr
Trade Receivables ₹107.6 Cr ₹106.94 Cr ₹93.21 Cr ₹75.14 Cr
Cash & Equivalents ₹5.12 Cr ₹69.23 Lakh ₹63.35 Cr ₹82.7 Lakh
Equity (Net Worth) ₹412.3 Cr ₹339.9 Cr ₹286.45 Cr ₹256.01 Cr
Equity Share Capital ₹94 Cr ₹94 Cr ₹94 Cr ₹94 Cr
Borrowings (Non-current) ₹0 ₹0 ₹0 ₹0
Borrowings (Current) ₹68.13 Lakh ₹4.04 Cr ₹71.65 Cr ₹83.18 Cr
Total Debt (computed) ₹68.13 Lakh ₹4.04 Cr ₹71.65 Cr ₹83.18 Cr
Current Liabilities ₹101.83 Cr ₹57.97 Cr ₹95.05 Cr ₹112.27 Cr
Total Liabilities ₹116.96 Cr ₹69.78 Cr ₹105.05 Cr ₹120.93 Cr
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Operating Cash Flow ₹58.29 Cr ₹23.31 Cr -₹5.94 Cr ₹10.5 Cr
Investing Cash Flow -₹50.64 Cr -₹18.38 Cr ₹83.83 Cr -₹44.97 Cr
Financing Cash Flow -₹3.22 Cr -₹67.59 Cr -₹15.37 Cr ₹35 Cr
Capital Expenditure ₹11.67 Cr ₹9.96 Cr ₹8.14 Cr ₹20.63 Cr
Free Cash Flow (computed) ₹46.62 Cr ₹13.35 Cr -₹14.07 Cr -₹10.14 Cr
Dividends Paid ₹0 ₹0 ₹0 ₹2.82 Cr
Net Change in Cash ₹4.43 Cr -₹62.66 Cr ₹62.52 Cr ₹52.53 Lakh
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹134 Cr ₹114.59 Cr ₹121.44 Cr ₹116.55 Cr ₹148.46 Cr ₹127.03 Cr ₹101.49 Cr ₹86.83 Cr ₹73.27 Cr ₹63.34 Cr ₹62.39 Cr ₹59.36 Cr
Other Income ₹14.23 Cr ₹5.48 Cr ₹5.23 Cr ₹6.02 Cr ₹6.9 Cr ₹3.82 Cr ₹4.18 Cr ₹1.31 Cr ₹2.87 Cr ₹4.35 Cr ₹4 Cr ₹1.88 Cr
Total Income ₹148.23 Cr ₹120.07 Cr ₹126.67 Cr ₹122.57 Cr ₹155.37 Cr ₹130.85 Cr ₹105.68 Cr ₹88.14 Cr ₹76.14 Cr ₹67.69 Cr ₹66.39 Cr ₹61.24 Cr
Cost of Materials Consumed ₹67.45 Cr ₹47.45 Cr ₹46.43 Cr ₹59.61 Cr ₹80.16 Cr ₹76.26 Cr ₹68.58 Cr ₹53.03 Cr ₹37.88 Cr ₹37.75 Cr ₹33.25 Cr ₹22.65 Cr
Purchases of Stock-in-Trade ₹20.15 Cr ₹15.57 Cr ₹15.35 Cr ₹15.62 Cr ₹15.68 Cr ₹7.13 Cr ₹12.6 Cr ₹4.06 Cr ₹4.89 Cr ₹3.98 Cr ₹8.2 Cr ₹9.14 Cr
Changes in Inventories -₹4.65 Cr -₹2.18 Cr ₹9.09 Cr -₹6.16 Cr ₹4.39 Cr ₹3.23 Cr -₹15.61 Cr -₹2.63 Cr -₹20.04 Lakh -₹2.8 Cr -₹3.09 Cr ₹3.91 Cr
Employee Benefit Expense ₹16.95 Cr ₹17.45 Cr ₹16.73 Cr ₹15.95 Cr ₹14.97 Cr ₹13.95 Cr ₹12.4 Cr ₹9.65 Cr ₹8.69 Cr ₹9.74 Cr ₹9 Cr ₹7.63 Cr
Finance Costs ₹36.71 Lakh ₹25 Lakh ₹25.03 Lakh ₹23.74 Lakh ₹8.92 Lakh ₹21.23 Lakh ₹16.22 Lakh ₹38.65 Lakh ₹1.17 Cr ₹1.08 Cr ₹1.08 Cr ₹1.12 Cr
Depreciation & Amortisation ₹2.48 Cr ₹1.36 Cr ₹1.35 Cr ₹1.34 Cr ₹1.29 Cr ₹1.31 Cr ₹1.3 Cr ₹1.3 Cr ₹1.3 Cr ₹1.45 Cr ₹87.88 Lakh ₹1.1 Cr
Other Expenses ₹12.62 Cr ₹15.12 Cr ₹15.11 Cr ₹15.75 Cr ₹15.78 Cr ₹11.86 Cr ₹11.59 Cr ₹12.25 Cr ₹13.2 Cr ₹7.88 Cr ₹8.93 Cr ₹9.88 Cr
Total Expenses ₹115.36 Cr ₹95.03 Cr ₹104.31 Cr ₹102.35 Cr ₹132.37 Cr ₹113.95 Cr ₹91.02 Cr ₹78.05 Cr ₹66.93 Cr ₹59.07 Cr ₹58.25 Cr ₹55.43 Cr
Profit Before Exceptional Items & Tax ₹32.87 Cr ₹25.05 Cr ₹22.36 Cr ₹20.22 Cr ₹23 Cr ₹16.9 Cr ₹14.65 Cr ₹10.1 Cr ₹9.21 Cr ₹8.62 Cr ₹8.14 Cr ₹5.81 Cr
Exceptional Items -₹44,000 ₹0 ₹0 ₹4.13 Lakh ₹82,000 ₹0 -₹24,000 ₹0 ₹0 -₹2.39 Lakh ₹0 ₹0
Profit Before Tax ₹32.86 Cr ₹25.05 Cr ₹22.36 Cr ₹20.26 Cr ₹23.01 Cr ₹16.9 Cr ₹14.65 Cr ₹10.1 Cr ₹9.21 Cr ₹8.6 Cr ₹8.14 Cr ₹5.81 Cr
Total Tax Expense ₹8.29 Cr ₹6.18 Cr ₹5.52 Cr ₹4.53 Cr ₹5.51 Cr ₹4.11 Cr ₹3.7 Cr ₹2.47 Cr ₹2.46 Cr ₹2.18 Cr ₹1.94 Cr ₹1.56 Cr
Net Profit ₹24.57 Cr ₹18.86 Cr ₹16.84 Cr ₹15.73 Cr ₹17.5 Cr ₹12.79 Cr ₹10.95 Cr ₹7.63 Cr ₹6.75 Cr ₹6.42 Cr ₹6.21 Cr ₹4.25 Cr
Other Comprehensive Income -₹9.95 Cr ₹2.36 Cr -₹5.58 Lakh ₹4.04 Cr -₹2.28 Cr ₹18.4 Lakh ₹3.92 Cr ₹2.76 Cr ₹1.65 Cr ₹1.86 Cr ₹1.24 Cr ₹2.07 Cr
Total Comprehensive Income ₹14.62 Cr ₹21.23 Cr ₹16.79 Cr ₹19.77 Cr ₹15.22 Cr ₹12.98 Cr ₹14.87 Cr ₹10.39 Cr ₹8.39 Cr ₹8.28 Cr ₹7.45 Cr ₹6.32 Cr
EBITDA (computed) ₹35.71 Cr ₹26.66 Cr ₹23.96 Cr ₹21.79 Cr ₹24.38 Cr ₹18.42 Cr ₹16.11 Cr ₹11.78 Cr ₹11.68 Cr ₹11.15 Cr ₹10.1 Cr ₹8.04 Cr
Basic EPS ₹0.26 ₹0.23 ₹0.18 ₹0.21 ₹0.16 ₹0.14 ₹0.16 ₹0.11 ₹0.09 ₹0.09 ₹0.08 ₹0.07
Diluted EPS ₹0.26 ₹0.23 ₹0.18 ₹0.21 ₹0.16 ₹0.14 ₹0.16 ₹0.11 ₹0.09 ₹0.09 ₹0.08 ₹0.07
Latest 12 quarters shown.
Segment · Q4 FY26 (latest quarter) Revenue Result (PBIT) Assets Liabilities
Pharmaceuticals Drugs & Formulations ₹147.26 Cr ₹32.86 Cr ₹435.18 Cr ₹115.23 Cr
Trading of Commodities ₹4.03 Lakh -₹4.35 Lakh ₹66.51 Lakh ₹4.12 Lakh
Renting of Property ₹92.49 Lakh ₹40.99 Lakh ₹93.42 Cr ₹1.68 Cr
Segment · FY 2026 (annual) Revenue Result (PBIT) Assets Liabilities
Pharmaceuticals Drugs & Formulations ₹512.74 Cr ₹98.66 Cr - -
Trading of Commodities ₹1.1 Cr -₹2.63 Lakh - -
Renting of Property ₹3.7 Cr ₹3 Cr - -
Want more history and ratios?
You're viewing the latest exchange-filed financials for Syncom Formulations (India) Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Syncom Formulations (India) Limited

As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 50.57%, foreign institutional investors hold 0.21%, domestic institutional investors hold 0.00%, retail and other public shareholders hold 49.21% of Syncom Formulations (India) Limited. The company had 431,690 shareholders on record.

Promoters: 50.57%FII (Foreign Institutional): 0.21%Retail & Others: 49.21%
Mar 2026
QUARTER
50.57% Promoters
0.21% FII (Foreign Institutional)
49.21% Retail & Others
Promoter holding - history
Now 50.57% · Mar 2026High 50.57% · Nov 2022Low 50.57% · Nov 2022
49%49.8%50.5%51.3%52%Nov 2022Jun 2023Mar 2024Dec 2024Sep 2025Nov 2022: 50.57%Dec 2022: 50.57%Mar 2023: 50.57%Jun 2023: 50.57%Sep 2023: 50.57%Dec 2023: 50.57%Mar 2024: 50.57%Jun 2024: 50.57%Sep 2024: 50.57%Dec 2024: 50.57%Mar 2025: 50.57%Jun 2025: 50.57%Sep 2025: 50.57%Dec 2025: 50.57%Mar 2026: 50.57%50.57%50.57%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Promoters50.57%50.57%50.57%50.57%50.57%50.57%
Public49.43%49.43%49.43%49.43%49.43%49.43%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024Mar 2023
Promoters50.57%50.57%50.57%50.57%
Public49.43%49.43%49.43%49.43%
Promoter change (YoY, %pts)+0.00+0.00+0.00-

Board & Governance of Syncom Formulations (India) Limited

As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Syncom Formulations (India) Limited has 6 directors - 3 independent and 3 executive. The board is chaired by Ankit Kedarmal Bankda.

DirectorPositionOn board sinceListed boards
Ankit Kedarmal Bankda Executive Director · Chairperson 2025-08-09 1
Kedarmal Shankarlal Bankda Executive Director 1992-04-13 1
Vijay Shankarlal Bankda Executive Director · MD 1999-12-01 1
Ruchi Jindal Non-Executive - Independent Director 2022-06-28 1
Ritesh Kumar Lunkad Non-Executive - Independent Director 2023-08-14 1
Ankit Jain Non-Executive - Independent Director 2023-08-14 1
Board Committees
CommitteeMembers
Audit Committee Ankit Jain (Chairperson), Ritesh Kumar Lunkad, Ruchi Jindal
Nomination and remuneration committee Ankit Jain (Chairperson), Ritesh Kumar Lunkad, Ruchi Jindal
Stakeholders Relationship Committee Ankit Jain (Chairperson), Ritesh Kumar Lunkad, Ruchi Jindal
Risk Management Committee Vijay Shankarlal Bankda (Chairperson), Ankit Kedarmal Bankda, Ankit Jain
Corporate Social Responsibility Committee Kedarmal Shankarlal Bankda (Chairperson), Vijay Shankarlal Bankda, Ankit Jain

Group Structure of Syncom Formulations (India) Limited

Syncom Formulations (India) Limited has 3 subsidiary companies. This group structure data is as of FY 2024. The corporate group structure reflects Syncom Formulations (India) Limited's business expansion strategy and organizational complexity.

3
Subsidiary companies
Key Subsidiaries
Company Name CIN Shares Held
Sante Biotech Private Limited U51909MP2022PTC061915 -
Synmex Pharma Private Limited U51909MP2022PTC061919 -
Vincit Biotech International Private Lim U51909MP2022PTC061970 -

Showing major subsidiaries. Total: 3.

Charges & Borrowings of Syncom Formulations (India) Limited

Open charges
₹9.5 Cr
Satisfied charges
₹156.68 Cr
Breakdown by lending institutions
Hdfc Bank Limited₹9.50 Cr
Latest charge details
DateLenderAmountStatus
01 Oct 2025 Hdfc Bank Limited ₹9.5 Cr Open
28 Dec 2020 Hdfc Bank Limited ₹100 Cr Satisfied
23 May 2002 Dena Bank ₹12.77 Cr Satisfied
23 May 2002 Dena Bank ₹12.77 Cr Satisfied
27 Mar 2000 Dena Bank ₹4 Cr Satisfied

Total charge records: 20 View all charges

Employees and EPFO Compliance at Syncom Formulations (India) Limited

Syncom Formulations (India) Limited has a workforce of 681 employees as of Mar 27, 2025.

Employee count
681
Active EPFO establishments
2
Employee growth
-17.25%
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Employee Count & EPFO Data of Syncom Formulations (India) Limited

Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.

Monthly employee headcount & PF contributions
EPFO establishment details & ECR filing status
Year-wise workforce analytics & attrition trends
PF exemption, coverage & compliance verification

GST Compliance of Syncom Formulations (India) Limited

XX%
Compliant
GSTR-1
GSTR-3B
GSTR-9
MH
KA
UP
TN
TS

GSTIN & GST Filing Data of Syncom Formulations (India) Limited

Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.

GSTIN registrations & state-wise presence
Filing compliance - GSTR-1, GSTR-3B, GSTR-9
HSN/SAC codes with goods & services details
Taxpayer type, jurisdiction & business constitution

Credit Ratings, Litigation & Regulatory Alerts for Syncom Formulations (India) Limited

Credit rating
AAA
AA+
AA
AA-
! !
2015 2017 2019 2021 2023
Litigation
District Court 35
High Court 45
Supreme Court 0
NCLT / NCLAT 0
Pending
Disposed
Regulatory alerts
GSTIN Cancelled
Andhra Pradesh
GSTIN Cancelled
Telangana (on application)
EPFO Delay
12 months delay - Haryana
Violations via Directors
20 MCA + 19 Bank defaults

Credit Ratings, Legal Cases & Regulatory Alerts of Syncom Formulations (India) Limited

Access complete credit rating history, litigation records, regulatory alerts, and compliance data.

Credit rating history across CARE, ICRA, Brickwork & India Ratings
Instrument-wise ratings, outlook & action timeline
Court-wise litigation (District, High Court, Supreme Court, NCLT)
Group company & common directorship litigation
Statutory compliance alerts (GSTIN, EPFO, ROC)
Director & company violations (MCA, SEBI, Banks, BSE/NSE)

MSME Payment Delays by Syncom Formulations (India) Limited

MSME Payment Delays by Syncom Formulations (India) Limited

Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.

Amounts outstanding to MSME suppliers
Delay periods & reasons for delayed payments
Half-yearly MSME-1 filing history
Vendor-payment behaviour as a counterparty risk signal

Subsidiaries & Group Companies of Syncom Formulations (India) Limited

Subsidiaries & Group Companies of Syncom Formulations (India) Limited

See the full corporate group - holding company, subsidiaries, associates and joint ventures of Syncom Formulations (India) Limited with ownership details.

Holding & parent company details
Subsidiaries & step-down subsidiaries with % holding
Associates & joint ventures with partner details
Investments in other entities year-on-year

MCA Filings & Documents of Syncom Formulations (India) Limited

MCA Filings & Documents of Syncom Formulations (India) Limited

Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.

Incorporation documents, MoA & AoA
Annual returns (MGT-7) & financial statements (AOC-4)
Charge filings (CHG-1, CHG-4) & resolutions
Complete document index with filing dates

Recent Activity on Syncom Formulations (India) Limited

Charges
01 Oct 2025
A charge with Hdfc Bank Limited amounted to Rs. 9.50 Cr with Charge ID 101172185 was registered on 01 Oct 2025.
Directors
08 Sep 2025
Rahul Vijay Bankda was appointed as a Cfo on 08 Sep 2025 & has been associated with this company since 10 months.
Directors
09 Aug 2025
Rahul Vijay Bankda was appointed as a CFO on 09 Aug 2025 & has been associated with this company since 11 months.
Directors
09 Aug 2025
Ankit Kedarmal Bankda was appointed as a Whole-time director on 09 Aug 2025 & has been associated with this company since 11 months.
Directors
08 Aug 2025
Vijay Shankarlal Bankda was appointed as a Officer in default on 08 Aug 2025 & has been associated with this company since 11 months 1 day.
Activity
31 Mar 2025
Syncom Formulations (India) Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai.

Recent News on Syncom Formulations (India) Limited

Frequently Asked Questions about Syncom Formulations (India) Limited

Syncom Formulations (India) Limited is an active public limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 21 June 1988 (38+ years old) and is registered under CIN L24239MH1988PLC047759. Listed on BSE: 524470. The company has 681 employees.

Syncom Formulations (India) Limited reported revenue of ₹482.45 Cr for FY 2025 (up 74.00% YoY).

The current directors of Syncom Formulations (India) Limited are:

The primary industry of Syncom Formulations (India) Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Syncom Formulations (India) Limited is listed on BSE with code 524470.

Syncom Formulations (India) Limited can be reached at the registered office: 7 Niraj Industrial Estate Off Mahakali Caves Road Andheri East, Mumbai, Maharashtra, India – 400093, or through the website sfil.in.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available